{"id":477439,"date":"2020-04-02T12:12:01","date_gmt":"2020-04-02T12:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477439"},"modified":"2020-04-02T12:12:01","modified_gmt":"2020-04-02T12:12:01","slug":"hemophilia-b-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-pipeline-insight-2020_477439.html","title":{"rendered":"Hemophilia B Pipeline Insight, 2020"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585812655.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hemophilia B Pipeline Insight, 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585812655.png\" alt=\"Hemophilia B Pipeline Insight, 2020\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on&nbsp;Hemophilia B Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Hemophilia B Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Hemophilia B&nbsp;market. A detailed picture of the&nbsp;Hemophilia B&nbsp;pipeline landscape is provided, which includes the disease overview and&nbsp;Hemophilia B&nbsp;treatment guidelines. The assessment part of the report embraces in-depth&nbsp;Hemophilia B&nbsp;commercial assessment and clinical assessment of the&nbsp;Hemophilia B&nbsp;pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;Hemophilia B&nbsp;collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>Hemophilia B<\/strong> is a genetic disorder caused by missing or defective Factor IX clotting protein.With the lack of this, the blood cannot clot properly to control bleedinglike hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.<\/p>\n<p style=\"text-align: justify;\">It is caused by an&nbsp;<strong>inherited X-linked recessive trait<\/strong>, with the defective gene located on the X chromosome. A male who has a hemophilia gene on his X chromosome will have hemophilia. When a female has a hemophilia gene on only one of her X chromosomes, she is a &#8220;hemophilia carrier&rdquo; and can pass the gene to her children. Sometimes carriers have low levels of clotting factor and have symptoms of hemophilia, including bleeding. Clotting factors are proteins in the blood that work together with platelets to stop or control bleeding.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/0442a1875a53c3d42881e6739c720ef4.JPG\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Request for<\/strong> :- <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight\" target=\"_blank\">free sample page<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span>All of the companies that are developing therapies for the treatment of&nbsp;<\/span><span>Hemophilia B&nbsp;<\/span><span>with aggregate therapies developed by each company for the same.<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;<\/span><span>Hemophilia B<\/span><span>&nbsp;treatment.<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Hemophilia B&nbsp;<\/span><span>key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;<\/span><span>Hemophilia B<\/span><span>&nbsp;market.<\/span><\/li>\n<\/ul>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Analytical Perspective&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span>In-depth Hemophilia B Commercial Assessment of products&nbsp;<\/span><\/li>\n<\/ul>\n<p class=\"ql-align-justify ql-indent-1\" style=\"text-align: justify;\"><span>This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span>Hemophilia B Clinical Assessment of products&nbsp;<\/span><\/li>\n<\/ul>\n<p class=\"ql-align-justify ql-indent-1\" style=\"text-align: justify;\"><span>The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/span><\/p>\n<p class=\"ql-align-justify ql-indent-1\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Reports Key facts:-&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1.&nbsp;&nbsp;<\/strong>According to the&nbsp;<strong>World Federation of Hemophilia (WFH)<\/strong>, the total number of cases around the World for Hemophilia B in 2018 was 34,289.<\/p>\n<p style=\"text-align: justify;\">2.&nbsp;<strong>Centers for Disease Control and Prevention<\/strong>states Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as hemophilia B, and about half of those affected have a severe form. Hemophilia affects people from all racial and ethnic groups. Additionally about 3 in 100 people with hemophilia B develop an inhibitor to the treatment product used to treat or prevent their bleeding episodes.<\/p>\n<p style=\"text-align: justify;\">3. As per&nbsp;<strong>Santoro, Cristina, et al.<\/strong>,&nbsp;<strong>2018,&nbsp;<\/strong>the development of an inhibitor in Hemophilia B is a rare event i.e., 1.5&ndash;3% of all patients but is associated with a significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.<\/p>\n<p style=\"text-align: justify;\"><em><strong>Key companies working on Hemophilia B that are given below:-<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><em><strong>1.&nbsp;<\/strong>&nbsp;Novo Nordisk Pharma Co.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong><em>2.&nbsp;&nbsp;<\/em><\/strong><em>CSL Behring Pharma Co.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><em>3.&nbsp;&nbsp;Bioverativ Therapeutics (a Sanofi acquired company)<\/em><\/p>\n<p style=\"text-align: justify;\"><strong><em>Drug names are given below:-&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>1.&nbsp;<\/em><\/strong><em>Rebinyn<\/em><\/p>\n<p style=\"text-align: justify;\"><em>2.&nbsp;Idelvion<\/em><\/p>\n<p style=\"text-align: justify;\"><em>3.&nbsp;Alprolix<\/em><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight#curriculum\" target=\"_blank\">Table of contents<\/a><\/p>\n<p style=\"text-align: justify;\"><span>1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Hemophilia B&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.1. Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.2. History&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.3. Hemophilia B Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.4. Causes<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.5.Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6. Hemophilia B Diagnosis&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6.1. Diagnostic Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Hemophilia B&nbsp;Current Treatment Patterns<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Hemophilia B Treatment Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Hemophilia B&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6. Hemophilia B Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\"><span>7. Hemophilia B Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Hemophilia B Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Hemophilia B&nbsp;Product Profiles<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14. Hemophilia B&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\"><span>15. Hemophilia B&nbsp;Key Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Dormant and Discontinued Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1. Dormant Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1.1. Reasons for being dormant<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2. Discontinued Products&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2.1. Reasons for the discontinuation<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. Hemophilia B&nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Hemophilia B&nbsp;Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Hemophilia B&nbsp;Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. Report Methodology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.1. Secondary Research<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.2. Expert Panel Validation<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22. About <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">Delveinsight<\/a><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">A better understanding of disease pathogenesis contributing to the development of novel therapeutics for&nbsp;<span>Hemophilia B<\/span>.&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<li class=\"ql-align-justify\">In the coming years, the&nbsp;<span>Hemophilia B&nbsp;<\/span>market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/li>\n<li class=\"ql-align-justify\"><span>The companies and academics that are working to assess challenges and seek opportunities that could influence&nbsp;<\/span><span>Hemophilia B&nbsp;<\/span><span>R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/li>\n<li class=\"ql-align-justify\">A detailed portfolio of major pharma players who are involved in fueling the&nbsp;<span>Hemophilia B&nbsp;<\/span><span>treatment market<\/span>. Several potential therapies for&nbsp;<span>Hemophilia B&nbsp;<\/span>are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the&nbsp;<span>Hemophilia B&nbsp;<\/span>market size in the coming years.&nbsp;&nbsp;<\/li>\n<li class=\"ql-align-justify\">Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of&nbsp;<span>Hemophilia B<\/span>) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Related Reports:-<\/strong><\/p>\n<p style=\"text-align: justify;\">1.&nbsp;<a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-market\">Hemophilia B &#8211; Market Insight, Epidemiology and Market Forecast -2030<\/a><\/p>\n<p style=\"text-align: justify;\">2.&nbsp;<a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a-pipeline-insight\">Hemophilia A &#8211; Pipeline Insights, 2020<\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hemophilia-b-pipeline-insight-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hemophilia-b-pipeline-insight-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight has launched a new report on&nbsp;Hemophilia B Market Insights, Epidemiology and Market Forecast-2030 &#8220;Hemophilia B Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Hemophilia B&nbsp;market. A detailed picture of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-pipeline-insight-2020_477439.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,420],"tags":[],"class_list":["post-477439","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477439"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477439\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}